Skip to content

Tai Chi Easy in Treating Cancer Survivors With Peripheral Sensory Neuropathy

Pilot Study of Effects of Tai Chi Easy on Cancer Survivors Experiencing Neuropathy

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01980368
Enrollment
0
Registered
2013-11-11
Start date
2013-08-31
Completion date
2017-01-18
Last updated
2018-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Survivor, Peripheral Sensory Neuropathy

Brief summary

This pilot clinical trial studies how well Tai Chi Easy works in treating cancer survivors with peripheral sensory neuropathy. Tai Chi Easy is a simple and repetitive form of exercise that consists of movements with meditation and may improve peripheral neuropathy symptoms among cancer survivors.

Detailed description

PRIMARY OBJECTIVES: I. Examine effects of Tai Chi Easy (TCEasy) exercise intervention on peripheral sensory neuropathy of cancer survivors who have chemotherapy compared with an educational control (EC) intervention. OUTLINE: Patients are randomized to 1 of 2 groups. GROUP I (TAI CHI EASY): Patients attend Tai Chi Easy class for 60 minutes once a week for 6 weeks. Patients also receive a DVD and exercise manual of Tai Chi Easy exercises and are encouraged to practice at home for 30 minutes most days per week for 6 weeks. GROUP II (EDUCATIONAL CONTROL): Patients receive readings each week and attend a book club to discuss the readings for 60 minutes once a week for 6 weeks. After completion of study, patients are followed up at 2 months.

Interventions

OTHEREducational Intervention

Receive readings and attend book club

BEHAVIORALExercise Intervention

Receive Tai Chi Easy class, DVD, and exercise manual

OTHERQuestionnaire Administration

Ancillary studies

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 1 month - 5 years following completion of cytotoxic chemotherapy treatment for any cancer, and are experiencing neuropathy * Self-report of \>= 4 on the Peripheral Neuropathy Question

Exclusion criteria

* Recurrence of cancer or other active cancer * Severe cachexia, dizziness, bone pain, or severe nausea (as judged by the investigator) * Uncontrolled diabetes, untreated hypothyroidism

Design outcomes

Primary

MeasureTime frameDescription
Change in peripheral sensory neuropathy, assessed by Peripheral Neuropathy Question, European Organization for Research and Treatment of Cancer (EORTC)-30, EORTC-Chemotherapy-induced peripheral neuropathy-20, and the modified Total Neuropathy ScoreBaseline up to 2 monthsWill be assessed with a simple t-test of mTNS means. Additional analyses of factors assessed will similarly be conducted (and overall analysis of variance when combining outcome variable assessment at the three time points, and models of factor contribution with logistic regression if appropriate).

Secondary

MeasureTime frameDescription
Changes in body mass index assessed by weight and heightBaseline up to 2 monthsWill be measured directly using standardized protocols with medical-quality calibrated balance scales.
Changes in cognitive performance assessed by digit span and letter-number sequencingBaseline up to 2 months
Changes in depression assessed by Program Operations Manual System (POMS) Total Mood Disturbance dimensions (depression-dejection)Baseline up to 2 months
Changes in anxiety assessed by POMS Total Mood Disturbance dimensions (tension-anxiety)Baseline up to 2 months
Changes in pain assessed by Medical Outcomes Study-Short Form 36Baseline up to 2 months
Changes in sleep quality assessed by Pittsburgh Sleep Quality Index and actigraphBaseline up to 2 months
Changes in fatigue assessed by Fatigue Symptom InventoryBaseline up to 2 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026